LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 30MG/30ML

Genentech, Inc. (UNITED STATES)🇸🇬 Health Sciences Authority

Approval Date: May 8, 2024
Approval ID: 655d495b533197ae
Company: Genentech, Inc. (UNITED STATES)
Type: Therapeutic

Approval Details

Approval Id: 655d495b533197ae
Drug Name: LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 30MG/30ML
Product Name: LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 30MG/30ML
Approval Number: SIN17002P
Approval Date: 2024-05-08
Registrant: ROCHE SINGAPORE PTE. LTD.
Licence Holder: ROCHE SINGAPORE PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: Prescription Only
Dosage Form: INFUSION, SOLUTION CONCENTRATE
Dosage: 2.2 DOSAGE AND ADMINISTRATION General Lunsumio must only be administered as an intravenous infusion under the supervision of a qualified healthcare professional with appropriate medical support to manage severe reactions such as cytokine release syndrome and neurologic toxicity. (see Section 2.4 Warnings and Precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Do not administer as an IV push or bolus. Prophylaxis and premedication Lunsumio should be administered to well-hydrated patients. Table 1 provides details on recommended premedication for cytokine release syndrome and infusion related reactions. <img src="/TGIF/Lunsumio-Table1.png" alt="Lunsumio Dosage Table 1" /> The recommended dose of Lunsumio for each 21-day cycle is detailed in Table 2. <img src="/TGIF/Lunsumio-Table2.png" alt="Lunsumio Dosage Table 2" /> Duration of Treatment Lunsumio should be administered for 8 cycles unless a patient experiences unacceptable toxicity or disease progression. For patients who achieve a complete response, no further treatment beyond 8 cycles is required. For patients who achieve a partial response or have stable disease in response to treatment with Lunsumio after 8 cycles, an additional 9 cycles of treatment (17 cycles total) should be administered, unless a patient experiences unacceptable toxicity or disease progression. Delayed or Missed Doses If any dose in cycle 1 is delayed for >7 days, the previous tolerated dose should be repeated prior to resuming the planned treatment schedule. If a dose interruption occurs between cycles 1 and 2 that results in a treatment-free interval of ≥6 weeks, administer Lunsumio at 1 mg on Day 1, 2 mg on Day 8, then resume the planned cycle 2 treatment of 60 mg on Day 15. If a dose interruption occurs that results in a treatment-free interval of ≥6 weeks between any cycles in cycle 3 onwards, administer Lunsumio at 1 mg on Day 1, 2 mg on Day 8, then resume the planned treatment schedule of 30 mg on Day 15. Dose Modifications Cytokine Release Syndrome Identify cytokine release syndrome (CRS) based on clinical presentation (see section 2.4 Warnings and Precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Evaluate for and treat other causes of fever, hypoxia, and hypotension, such as infections/sepsis. Infusion related reactions (IRR) may be clinically indistinguishable from manifestations of CRS. If CRS or IRR is suspected, manage according to the recommendations in Table 3. <img src="/TGIF/Lunsumio_281024-Table3.png" alt="Lunsumio Dosage Table 3" /> Neurologic Toxicity Including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Management recommendations for neurologic toxicity, including ICANS, is summarized in Table 4. At the first sign of neurologic toxicity, including ICANS, withhold Lunsumio for grade 2 and above and consider neurology evaluation. Rule out other causes of neurologic symptoms. Provide supportive therapy, which may include intensive care. <img src="/TGIF/Lunsumio_281024-Table4.png" alt="Lunsumio Dosage Table 4" /> Dose modifications for other clinically significant adverse reactions Patients who experience grade 3 or 4 reactions should have treatment temporarily withheld until symptoms are resolved. 2.2.1 Special Dosage Instructions Pediatric use The safety and efficacy of Lunsumio in children below 18 years of age have not been established. Geriatric use No dose adjustment of Lunsumio is required in patients ≥ 65 years of age (see section 2.5.5 Use in Special Populations, Geriatric Use – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Renal Impairment No dose adjustment is required in patients with mild or moderate renal impairment. A recommended dose has not been determined for patients with CrCl <30 mL/min (see sections 2.5.6 Renal Impairment and 3.2.5 Pharmacokinetics in Special Populations – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Hepatic Impairment No dose adjustment of Lunsumio is required for patients with mild hepatic impairment [total bilirubin greater than upper limit of normal (ULN) and ≤ 1.5x ULN or aspartate transaminase greater than ULN]. (see 2.5.7 Hepatic Impairment and 3.2.5 Pharmacokinetics in special populations – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). A recommended dose has not been determined for Lunsumio in patients with moderate or severe hepatic impairment.
Route Of Administration: INTRAVENOUS
Indication Info: 2.1 THERAPEUTIC INDICATION(S) Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.
Contraindications: 2.3 CONTRAINDICATIONS Lunsumio is contraindicated in patients with a known hypersensitivity to mosunetuzumab or any of the excipients.
Atc Code: L01FX25
Pharma Manufacturer Name: ROCHE SINGAPORE PTE. LTD.

Active Ingredients

Mosunetuzumab

30 mg/30 ml

Mosunetuzumab

30 mg/30 ml

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

May 8, 2024

Approval ID

655d495b533197ae

Type

Therapeutic

Back to HSA Approvals